https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/nice-recommend-drug-trialled-gosh-treatment-duchenne-muscular-dystrophy/
NICE recommend drug trialled at GOSH for the treatment of Duchenne Muscular Dystrophy
16 Sep 2016, 11:02 a.m.
NICE have published final guidance recommending ataluren for the treatment of Duchenne Muscular Dystrophy (DMD) caused by a nonsense mutation, in children aged 5 years and over who are able to walk.
DMD is a severe, muscle-wasting condition caused by a fault in a gene, resulting in a failure to produce functional dystrophin; currently DMD has few treatment options.
Ataluren is a novel drug, aimed at the root cause of the disease, allowing the body to continue to produce dystrophin by reading over the mutation in the DNA. Ataluren targets a specific change in the DNA called a nonsense mutation, which affects approximately 13% of Duchenne sufferers. Research in which GOSH recruited a substantial number of patients, has suggested that ataluren could delay the loss of walking in these patients by up to 7 years.
A 5-year managed access agreement for ataluren has been arranged, permitting patients with this disorder to access the drug whilst allowing more data to be collected on the drug’s efficacy.
Read full article here.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)
Important step forward in stem cell therapy for rare bowel disease
A new study led by researchers at UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and the Centre for Stem Cell Biology, University of Sheffield, has demonstrated the potential of stem cell therapy to treat those with Hirschsprung disease.
First UK trial of Deep Brain Stimulation for children with epilepsy begins at GOSH
Discover how Oran became the first UK patient in a clinical trial using deep brain stimulation (DBS) for epilepsy. Learn about his 80% reduction in daytime seizures thanks to this innovative DBS treatment.